4.6 Article

IgA Nephropathy

出版社

AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.07420716

关键词

-

资金

  1. Shire Viropharma (Lexington, MA)
  2. Astra Zeneca (Wilmington, DE)
  3. Hoffman La-Roche (Mississauga, ON, Canada)

向作者/读者索取更多资源

IgA nephropathy (IgAN) is a leading cause of CKD and renal failure. Recent international collaborative efforts have led to important discoveries that have improved our understanding of some of the key steps involved in the immunopathogenesis of IgAN. Furthermore, establishment of multicenter networks has contributed to rigorous design and execution of clinical trials that have provided important insights regarding immunotherapy in IgAN. In this article, we review emerging developments in clinical and translational IgAN research and describe how these novel findings will influence future strategies to improve the outcome of patients with IgAN.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据